IP Library Granted Patent US 8,883,849
Granted Patent B2
US 8,883,849 · App. 13/584,054 · Granted Nov 11, 2014

Treatment of sleep disturbances

Inventors: Graham D. Cook (Midlothian, VA); Todd S. Koch (Powhatan, VA); David H. Giamalva (Glen Allen, VA); Justin Bianco (Vineland, NJ); James J. Fort (Midlothian, VA); Geraldine Doyle (Chatham, NJ); Steven Cooper (Denville, NJ)
Assignee: Wyeth LLC
A61K31/137A61K31/192A61K9/4858A61K9/209
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,849
App. No.
13/584,054
Granted
Nov 11, 2014
Kind
B2
Abstract

The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.

Claims (34)

1. A method of treating a patient suffering from a pain-associated sleep disturbance comprising administering a liquid composition formulated inside a soft gelatin capsule to the patient,

wherein the liquid composition consists of:

from about 200 to about 400 mg of ibuprofen;

from about 10 to about 50 mg of diphenhydramine;

polyethylene glycol;

potassium hydroxide; and

water.

2. The method of claim 1 , wherein the sleep disturbance affects sleep duration.

3. The method of claim 1 , wherein the ibuprofen and diphenhydramine are dissolved in the polyethylene glycol, potassium hydroxide and water solution.

4. The method of claim 1 , wherein the diphenhydramine is present as diphenhydramine HCI or diphenyhydramine citrate.

5. The method of claim 4 , wherein the diphenhydramine HCI is present in a range from about 12.5 mg to about 50 mg.

6. The method of claim 5 , wherein the diphenhydramine HCI is present in a range from about 25 mg to about 50 mg.

7. The method of claim 6 , wherein the diphenhydramine HCI is present in an amount of about 25 mg.

8. The method of claim 4 , wherein the diphenhydramine citrate is present in a range from about 19 mg to 38 mg.

9. The method of claim 8 , wherein the diphenhydramine citrate is present in an amount of 38 mg.

10. The method of claim 1 , wherein the ibuprofen is present in a range from about 200 mg to about 300 mg.

11. The method of claim 10 , wherein the ibuprofen is present in an amount about 200 mg.

12. The method of claim 1 , wherein one dose of the composition is administered.

13. The method of claim 1 , wherein two doses of the composition are administered.

14. The method of claim 1 , wherein one dose of the composition is administered and a second dose is optionally administered.

15. A method of treating a patient suffering from a pain-associated sleep disturbance comprising administering a liquid composition formulated inside a soft gelatin capsule to the patient,

wherein the liquid composition consists of:

from about 200 mg to about 400 mg ibuprofen,

from about 12.5 mg to about 50 mg diphenhydramine, polyethylene glycol,

potassium hydroxide, and

water.

16. The method of claim 15 , wherein the diphenhydramine is present as diphenhydramine HCI or diphenyhydramine citrate.

17. The method of claim 16 , wherein the diphenhydramine HCI is present in an amount of about 25 mg.

18. The method of claim 16 , wherein the diphenhydramine citrate is present in an amount of 38 mg.

19. The method of claim 15 , wherein the ibuprofen is present in an amount about 200 mg.

20. The method of claim 15 , wherein the ibuprofen and diphenhydramine are dissolved in the polyethylene glycol,potassium hydroxide and water solution.

21. The method of claim 15 , wherein one dose of the composition is administered.

22. The method of claim 15 , wherein two doses of the composition are administered.

23. The method of claim 15 , wherein one dose of the composition is administered and a second dose is optionally administered.

Assignments (4)
CHANGE OF NAME Recorded Mar 1, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066713/0558 →
CHANGE OF NAME Recorded Feb 28, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066701/0387 →
MERGER AND CHANGE OF NAME Recorded Apr 6, 2022
From: PF CONSUMER HEALTHCARE 1 LLC; GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
Reel/Frame 059620/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: WYETH LLC
To: PF CONSUMER HEALTHCARE 1 LLC
Reel/Frame 050727/0184 →
Continuity (4)
Continuation 12082342 · Apr 10, 2008
Continuation 10046727 · Jan 17, 2002
Provisional Application 60262387 · Jan 19, 2001
Related Publication 20120308483A1 · Dec 6, 2012